REGN7075
Sponsors
Regeneron Pharmaceuticals Inc., Regeneron Pharmaceuticals, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Conditions
Advanced Solid TumorsAdvanced/Metastatic Non-Small Cell Lung CancerColorectal CancerNon-Small Cell Lung CancerSolid Tumours
Phase 1
A Trial to Find Out How Safe REGN7075 is and How Well it Works in Combination With Cemiplimab for Adult Participants With Advanced Cancers
RecruitingNCT04626635
Start: 2020-12-21End: 2027-04-07Target: 933Updated: 2026-02-02
A Phase 1/2 Study of REGN7075 (EGFRxCD28 Costimulatory Bispecific Antibody) in Combination with Cemiplimab in Patients with Advanced Solid Tumors
RecruitingCTIS2022-501234-37-00
Start: 2024-05-07Target: 212Updated: 2025-09-16
Phase 2
A Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer Treatments for Adult Patients With Operable Non-Small Cell Lung Cancer (NSCLC)
RecruitingNCT06465329
Start: 2024-11-18End: 2030-05-02Target: 120Updated: 2026-02-12
A Randomized Phase 2 Platform Study to Evaluate Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer Treatments for the Perioperative Treatment of Patients with Resectable Non-Small Cell Lung Cancer
RecruitingCTIS2023-509806-31-00
Start: 2025-02-11Target: 40Updated: 2025-11-07
A Study to Investigate Ubamatamab With and Without REGN7075 in Adult Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)
RecruitingNCT07154290
Start: 2026-03-18End: 2030-06-24Target: 300Updated: 2026-03-27
Capecitabine/Oxaliplatin Chemotherapy and Cemiplimab With or Without Fianlimab or REGN7075 in Locally Advanced Rectal Cancer
Not yet recruitingNCT07281768
Start: 2026-04-01End: 2030-04-01Target: 66Updated: 2026-03-20